Eisai's US perampanel resubmission accepted for review
This article was originally published in Scrip
The US FDA has formally accepted for review Eisai's resubmission of a new drug application for its novel epilepsy product perampanel, setting the Prescription Drug User Fee Act target date for 22 October.
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.